News Column

Studies from Johns Hopkins University Bloomberg School of Public Health Provide New Data on Conjugate Vaccines

February 12, 2014

By a News Reporter-Staff News Editor at Vaccine Weekly -- Investigators publish new report on Biotechnology. According to news originating from Baltimore, Maryland, by NewsRx correspondents, research stated, "Invasive disease due to Streptococcus pneumoniae remains an important worldwide cause of morbidity and mortality, particularly in young children and the elderly. The development and use of pneumococcal conjugate vaccines (PCVs) have had a dramatic impact on rates of vaccine-type invasive pneumococcal disease (IPD) not only in the pediatric population targeted for vaccination but in non-vaccinated age-groups as well."

Our news journalists obtained a quote from the research from the Johns Hopkins University Bloomberg School of Public Health, "This indirect effect is directly mediated by a reduction of vaccine-type nasopharyngeal carriage and thus transmission by vaccinated children. Current PCV licensing procedures do not take into consideration nasopharyngeal carriage impact, and thus the indirect effect. This review summarizes the evidence for the indirect effect of PCV on vaccine-type disease and its correlation with changes in carriage among unvaccinated populations, to assess the basis for inclusion of carriage in the PCV licensing process. Randomized controlled trials, surveillance and other observational studies published between 1994 and 2013 were systematically identified from global, regional and review databases and conference abstracts. We included as primary evidence, studies in non-vaccinated groups addressing changes in both vaccine-type IPD and carriage between pre- and post-PCV introduction periods; studies missing one of these four components were included as supporting rather than primary evidence. We identified studies from 14 countries, nearly all developed countries. Vaccine-type IPD and carriage in non-targeted populations consistently decreased after PCV introduction, with the magnitude of decrease growing over time. Where IPD and carriage were observed in the same population, VT-decreases occurred contemporaneously. These relationships held true across age-groups and between indigenous and non-indigenous populations in the US and Australia. Indirect PCV impact on VT-IPD and VT-carriage has been significant."

According to the news editors, the research concluded: "Impact on carriage should be considered for inclusion in the PCV licensure process as a predictor of indirect effects."

For more information on this research see: Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: Review of evidence on indirect effects. Vaccine, 2013;32(1):133-145. Vaccine can be contacted at: Elsevier Sci Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. (Elsevier -; Vaccine -

The news correspondents report that additional information may be obtained from S.M. Davis, Johns Hopkins Bloomberg Sch Public Hlth, Center Amer Indian Hlth, Dept. of Int Hlth, Baltimore, MD, United States. Additional authors for this research include M. Deloria-Knoll, H.T. Kassa and K.L. O'Brien (see also Biotechnology).

Keywords for this news article include: Biotechnology, Maryland, Baltimore, Pediatrics, United States, Conjugate Vaccines, Synthetic Vaccines, Biological Products, Pneumococcal Disease, Pneumococcal Infections, Streptococcal Infections, North and Central America, Clinical Trials and Studies, Gram-Positive Bacterial Infections

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Vaccine Weekly

Story Tools